• 1
    Blackard CE. The Veterans Administration Cooperative Urological Research Group Study of Carcinoma of the Prostate: a review. Cancer Chemother Rep 1975; 59: 2257
  • 2
    Glashan RW, Robinson MG. Cardiovascular complications in the treatment of prostatic cancer. Br J Urol 1981; 53: 6247
  • 3
    Seidenfeld J, Samson DJ, Hasselblad V et al. Single-agent androgen suppression in men with advanced prostate cancer. a systematic review and meta-analysis. Ann Intern Med 2000; 132: 56677
  • 4
    Coy DH, Labrie F, Savary M et al. LH-releasing activity of potent LH-RH analogs in vitro. Biochem Biophys Res Comm 1975; 67: 57682
  • 5
    Coy DH, Vilchez-Martinez JA, Coy EJ et al. Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by d-amino acid substitutions in position 6. J Med Chem 1976; 19: 4235
  • 6
    Barron JL, Millar RP, Searle D. Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 1982; 54: 116973
  • 7
    Scott J, Huskisson EC. Graphic representation of pain. Pain 1987; 2: 17584
  • 8
    Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 36576
  • 9
    Sharifi R, Soloway M. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group. J Urol 1990; 143: 6871